PDCD1 and neoplasm: Compared to vehicle control mice, anti-PD-1-treated mice displayed reduction in tumor size, indicating loss of anti-PD-1 resistance in β-catenin-deficient tumors (Fig. 5a and Supplementary Fig. 14a–d).